TIDMPRTC
PureTech Health PLC
07 May 2019
7 May 2019
PureTech Health plc
PureTech's Vedanta Biosciences Announces Favourable Decision for
Key Microbiome Patent
European Patent Office decision further solidifies Vedanta's
leading IP position in the microbiome therapeutic field
PureTech Health plc (LSE:PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to
announce that the European Patent Office has issued a decision to
uphold Vedanta Bioscience's foundational patent EP2575835 (the
"Honda patent"). This patent covers compositions of clostridial
bacterial species for use in infectious and allergic disease, and
is based on groundbreaking work by Dr Kenya Honda, a scientific
co-founder of Vedanta Biosciences. The Honda patent is exclusively
licensed to Vedanta under an agreement with the University of Tokyo
and provides coverage through at least 2031.
This decision reinforces Vedanta's leadership position in the
microbiome field as clostridial species are abundant in the gut and
due to their immunomodulatory potential are of core interest for
use in the development of live biotherapeutic products designed to
colonise and modulate a patient's microbiome to therapeutic
effect.
Bharatt Chowrira, JD, PhD, president and chief of business and
strategy at PureTech Health, said: "In an emerging field as novel
as microbiome therapies, capturing the value of groundbreaking
discoveries is crucial to build a long-term foundation for IP
leadership. Vedanta has always ensured its broad platform for
therapeutic discovery and development has been supported by a
strategic and comprehensive intellectual property portfolio, so
this decision reflects both that long-term strategy and the truly
novel contributions of Dr Honda."
The full text announcement from Vedanta is as follows:
Vedanta Biosciences Key Microbiome Patent Upheld in European
Opposition Proceedings
Upheld patent EP2575835 covers therapeutic compositions of
clostridial bacterial species derived from the human microbiome
Decision further solidifies Vedanta's leading IP position in the
microbiome therapeutic field
CAMBRIDGE, Mass., May 7, 2019 - Vedanta Biosciences, a
clinical-stage company developing a new category of therapies for
immune-mediated diseases based on rationally-defined consortia of
human microbiome-derived bacteria, today announced that the
Opposition Division of the European Patent Office has upheld
Vedanta's foundational patent EP2575835 (the "Honda patent"),
strengthening Vedanta's intellectual property position in a key
area of microbiome therapeutics. The patent is based on
groundbreaking work by Dr Kenya Honda, a scientific co-founder of
Vedanta Biosciences, in identifying bacteria that induce
significant immune responses. The upheld patent claims broadly
cover compositions of clostridial bacterial species for use in
infectious and allergic disease.
Clostridial bacterial species are abundant in the gut and are of
high interest for use in the development of live biotherapeutic
products designed to colonise and modulate a patient's microbiome
to therapeutic effect. The Honda patent is exclusively licensed to
Vedanta under an agreement with the University of Tokyo and
provides coverage through at least 2031.
"We welcome this decision which affirms our belief that Dr
Honda's breakthrough discoveries form the basis for a critical,
foundational patent estate for the development and
commercialisation of human microbiome drugs based on live
bacteria," said Bernat Olle, PhD, chief executive officer of
Vedanta Biosciences.
The Honda patent, together with additional Vedanta patents,
provide the company with a leading IP position in the microbiome
field. Vedanta's patents support the company's therapeutic
candidates for the treatment of autoimmune diseases, such as
inflammatory bowel disease (IBD), food allergy, and infectious
diseases. Vedanta's portfolio contains 20 US patents and numerous
foreign issuances with coverage extending to 2037.
The Honda patent, EP2575835, was opposed by six parties: Seres
Therapeutics Inc., Nestec SA (a subsidiary of Nestlé SA) and four
anonymous parties. Minor formal claim amendments were entered
during the oral proceedings. The patent is now issued in major
commercial markets, including the United States, Europe, and
Japan.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage company developing a new
category of therapies for immune-mediated diseases based on
rationally-defined consortia of human microbiome-derived bacteria.
Vedanta Biosciences is a leader in the microbiome field with
capabilities and deep expertise to discover, develop, and
manufacture live bacteria drugs. These include what is believed to
be the largest collection of human-gut associated bacteria, a suite
of proprietary assays to select pharmacologically potent strains,
vast proprietary datasets from human interventional studies, and
facilities for cGMP-compliant manufacturing of rationally-defined
bacterial consortia in powder form. Vedanta Biosciences' pioneering
work, in collaboration with its scientific co-founders, has led to
the identification of human commensal bacteria that induce a range
of immune responses - including induction of regulatory T cells,
CD8+ T cells, and Th17 cells, among others. These advances have
been published in leading peer-reviewed journals, including Science
(multiple), Nature (2013, 2019), Cell, and Nature Immunology.
Vedanta Biosciences has harnessed these biological insights and its
capabilities to generate a pipeline of programmes in infectious
disease, autoimmune disease, allergy, and immuno-oncology.
Vedanta Biosciences was founded by PureTech Health (LSE.PRTC).
Its scientific co-founders are world-renowned experts in immunology
and microbiology who have pioneered the fields of innate immunity,
Th17 and regulatory T cell biology, and include Ruslan Medzhitov,
PhD, (Yale and Howard Hughes Medical Institute (HHMI)), Brett
Finlay, PhD, (University of British Columbia and HHMI), Kenya
Honda, PhD, (Keio University and RIKEN), Dan Littman, PhD, (New
York University and HHMI), Alexander Rudensky, PhD, (Sloan
Kettering and HHMI), and Jeremiah Faith, PhD, (Mount Sinai School
of Medicine).
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health is developing new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech's affiliates include seven clinical-stage platforms,
including one product that has been cleared by the US Food and Drug
Administration (FDA) and a second product candidate that has been
filed with the FDA for review, and several other novel preclinical
programmes. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world's leading experts.
PureTech's internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEANSKEAANEFF
(END) Dow Jones Newswires
May 07, 2019 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024